Cargando…

Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance

Sorafenib is a small molecule that blocks tumor proliferation by targeting the activity of multi-kinases for the treatment of advanced hepatocellular carcinoma (HCC). Increasing sorafenib resistance following long-term treatment is frequently encountered. Mechanisms underlying sorafenib resistance r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Yung-Sheng, Su, Chien-Wei, Chen, San-Chi, Chen, Yen-Ying, Liang, Yuh-Jin, Wu, Jaw-Ching
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870465/ https://www.ncbi.nlm.nih.gov/pubmed/35203285 http://dx.doi.org/10.3390/cells11040634

Ejemplares similares

USP22 upregulates ZEB1-mediated VEGFA transcription in hepatocellular carcinoma
por: Zeng, Kai, et al.
Publicado: (2023)

USP29-mediated HIF1α stabilization is associated with Sorafenib resistance of hepatocellular carcinoma cells by upregulating glycolysis
por: Gao, Ruize, et al.
Publicado: (2021)

Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy
por: Xu, Shengjun, et al.
Publicado: (2021)

Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression Through Transcriptional Regulation of Epithelial‐Mesenchymal Transition Regulators and Stemness Genes
por: Chen, Chih‐Li, et al.
Publicado: (2018)

ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma
por: Huang, Wenbin, et al.
Publicado: (2021)

USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma
por: Ning, Zhen, et al.
Publicado: (2022)

High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients
por: Wang, Shen-Yung, et al.
Publicado: (2019)

Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells
por: Zhang, Keqiang, et al.
Publicado: (2023)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

High USP22 expression indicates poor prognosis in hepatocellular carcinoma
por: Tang, Bo, et al.
Publicado: (2015)

Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma
por: Tang, Bo, et al.
Publicado: (2023)

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)

The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases
por: Gan, Guifang, et al.
Publicado: (2021)

FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
por: Gao, Lixia, et al.
Publicado: (2017)

EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis
por: Fan, Chi-Chen, et al.
Publicado: (2020)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma
por: Li, Danyang, et al.
Publicado: (2022)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma
por: Stefanovic, Milica, et al.
Publicado: (2016)

DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation
por: Lai, Ssu-Chuan, et al.
Publicado: (2019)

Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation
por: Lai, Ssu-Chuan, et al.
Publicado: (2020)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
por: Lee, I-Cheng, et al.
Publicado: (2022)

Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib
por: Kuo, Yuan-Hung, et al.
Publicado: (2022)

Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30
por: Guo, Zhigui, et al.
Publicado: (2016)

Anterior gradient 2 induces resistance to sorafenib via endoplasmic reticulum stress regulation in hepatocellular carcinoma
por: Tsai, Hung-Wen, et al.
Publicado: (2023)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

CircFMN2 Boosts Sorafenib Resistance in Hepatocellular Carcinoma Cells via Upregulating CNBP by Restraining Ubiquitination
por: Fan, Chen, et al.
Publicado: (2022)

High USP32 expression contributes to cancer progression and is correlated with immune infiltrates in hepatocellular carcinoma
por: Xiu, Mengxi, et al.
Publicado: (2023)

The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma
por: Cheng, Chiung-Chi, et al.
Publicado: (2019)

Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells
por: Xu, Gui-Li, et al.
Publicado: (2020)

The ubiquitin hydrolase, USP22 contributes to 3’-end processing of JAK-STAT inducible genes
por: Chipumuro, Edmond, et al.
Publicado: (2013)

TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
por: Lai, Hui‐Huang, et al.
Publicado: (2019)

DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma
por: Chen, Xin, et al.
Publicado: (2022)

Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma
por: Ho, Chun-Ming, et al.
Publicado: (2022)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study
por: Kok, Victor C., et al.
Publicado: (2019)

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

The relationship between the expression of USP22, BMI1, and EZH2 in hepatocellular carcinoma and their impacts on prognosis
por: Zhai, Run, et al.
Publicado: (2016)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_94r6maapcc8kts111chkcltt1q